Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.52 |
| ▸ | TK1 | P04183 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748858 | 1.00 | PYGM (0.52) | PYGMTK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1130181 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM | |
| SCHEMBL6760136 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM | |
| SCHEMBL6314490 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM | |
| SCHEMBL3415528 | 0.84 | TK1 (0.60) | PYGMTK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL6753208 | 0.84 | SMN1; SMN2 (0.54) | PYGMTK1LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1129572 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM | |
| SCHEMBL6752642 | 0.84 | LMNA (0.60) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL1129570 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM | |
| SCHEMBL7701755 | 0.84 | LMNA (0.55) | TK1LMNAADRA1ATSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956021-B1 | L-BETA-DIOXOLANE URIDINE ANALOGS FOR TREATING AND PREVENTING INFECTIONS BY EBV, VZV AND HV-8 | UNIV YALE (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | YALE UNIVERSITY AND THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-08-30 | — | — | US | disclosed |
| US-6274589-B1 | VIRICIDES TO TREAT EPSTEIN-BARR, VARICELLA-ZOSTER, AND/OR HERPES INFECTIONS; KAPOSI'S SARCOMA | YALE UNIVERSITY | 2001-08-14 | — | — | US | disclosed |
| EP-0956021-A1 | L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998020879-A1 | L-β-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS | YALE UNIVERSITY (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018440-A1 | L-beta-dioxolane uridine analogs and methods for treating and preventing virus infections | UNG, DDX18, UMPS | PYGM 2159/4885TK1 30/4885LMNA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.